The prevalence of Esophageal Squamous Cell Carcinoma has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing
INDIANAPOLIS (dpa-AFX) - Innovent Biologics Inc. said that the National Medical Products Administration or NMPA of China has approved the supplemental New Drug Application or sNDA for CYRAMZA (ramucirumab)
/PRNewswire/ Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.
/PRNewswire/ The "PD-1 And PD-L1 Inhibitors Market by Application (solid tumors and blood-related tumors) and Geography (North America, Europe, Asia, and.